Results 101 to 110 of about 2,087,811 (325)

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

A spectral differential characterization of low-mass companions

EPJ Web of Conferences, 2013
We present a new approach with which the dynamical mass of low-mass companions around cool stars can be found. In order to discover companions to late-type stars the stellar spectrum is removed.
Lyubchik Y., Yakobchuk T., Kostogryz N., Kürster M., Kuznetsov M.   +4 more
doaj   +1 more source

Mass spectrum of gapped, non-confining theories with multi-scale dynamics

Journal of High Energy Physics, 2019
We study the mass spectrum of spin-0 and spin-2 composite states in a one-parameter family of three-dimensional field theories by making use of their dual descriptions in terms of supergravity.
Daniel Elander, Antón F. Faedo, David Mateos, David Pravos, Javier G. Subils   +4 more
doaj   +1 more source

BPS mass spectrum from D-brane action

, 1996
We derive the BPS mass formulae of the Dirichlet branes from the Born-Infeld type action. BPS saturation is realized when the brane has the minimal volume while keeping the appropriate winding numbers. We apply the idea to two cases, type IIA superstring
Aspinwall, Aspinwall, Becker, Bershadsky, Callan, Callan, Callan, Callan, Dabholkar, Dai, Dine, Douglas, Fradkin, Giveon, H. Ishikawa, Harvey, Horowitz, Hull, Ishibashi, K. Sugiyama, Kikkawa, Leigh, Li, Narain, Narain, Polchinski, Polchinski, Polchinski, Sakai, Schmidhuber, Schwarz, Schwarz, Schwarz, Seiberg, Sen, Sen, Sen, Sen, Strominger, Townsend, Vafa, Vafa, Witten, Witten, Witten, Y. Matsuo, Y. Sugawara, Yau   +47 more
core   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

Inclusive $B \to X_c l \nu$ decay spectra at Belle and the determination of $|V_{cb}|$

, 2006
We report measurements of the inclusive electron energy spectrum and hadron invariant mass spectrum for charmed semileptonic decays of B mesons in a 140 fb^-1 data sample collected with the Belle detector at the KEKB e+e- collider. We determine the first
Urquijo, Phillip
core   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Recovery of the Shape of the Mass Power Spectrum from the Lyman-alpha Forest

, 1998
We propose a method for recovering the shape of the mass power spectrum on large scales from the transmission fluctuations of the Lyman-alpha forest, which takes into account directly redshift-space distortions.
Cole S., Fisher K., Fisher K., Heavens A., Hui L., Kaiser N., Miralda-Escude J., Peacock J., Pen U., Taylor A.   +9 more
core   +3 more sources

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source